EP1165773A4 - Advanced antigen presentation platform - Google Patents

Advanced antigen presentation platform

Info

Publication number
EP1165773A4
EP1165773A4 EP00908430A EP00908430A EP1165773A4 EP 1165773 A4 EP1165773 A4 EP 1165773A4 EP 00908430 A EP00908430 A EP 00908430A EP 00908430 A EP00908430 A EP 00908430A EP 1165773 A4 EP1165773 A4 EP 1165773A4
Authority
EP
European Patent Office
Prior art keywords
antigen presentation
presentation platform
advanced
advanced antigen
platform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00908430A
Other languages
German (de)
French (fr)
Other versions
EP1165773A1 (en
Inventor
Timothy P Coleman
Darrell L Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioCache Pharmaceuticals Inc
Original Assignee
BioCache Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioCache Pharmaceuticals Inc filed Critical BioCache Pharmaceuticals Inc
Publication of EP1165773A1 publication Critical patent/EP1165773A1/en
Publication of EP1165773A4 publication Critical patent/EP1165773A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
EP00908430A 1999-02-02 2000-02-02 Advanced antigen presentation platform Withdrawn EP1165773A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11852699P 1999-02-02 1999-02-02
US118526P 1999-02-02
PCT/US2000/002413 WO2000046365A1 (en) 1999-02-02 2000-02-02 Advanced antigen presentation platform

Publications (2)

Publication Number Publication Date
EP1165773A1 EP1165773A1 (en) 2002-01-02
EP1165773A4 true EP1165773A4 (en) 2005-01-05

Family

ID=22379155

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00908430A Withdrawn EP1165773A4 (en) 1999-02-02 2000-02-02 Advanced antigen presentation platform

Country Status (4)

Country Link
EP (1) EP1165773A4 (en)
JP (1) JP2003520568A (en)
AU (1) AU2977500A (en)
WO (1) WO2000046365A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
NZ517929A (en) * 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
EP1651258B1 (en) * 2003-07-30 2014-03-19 Vaccine Research Institute of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7144712B2 (en) 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
RU2476595C2 (en) 2006-06-12 2013-02-27 Цитос Биотехнологи Аг Methods of packaging of oligonucleotides into virus-like particles of rna-containing bacteriophages
JP5389662B2 (en) 2006-12-12 2014-01-15 サイトス バイオテクノロジー アーゲー Oligonucleotides containing high concentrations of guanine monomer
CN111593138A (en) * 2019-09-20 2020-08-28 山东省农业科学院家禽研究所 Duck hepatitis B virus recombinant polymerase isothermal amplification detection method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07252300A (en) * 1994-03-11 1995-10-03 Immuno Japan:Kk Antigen fused protein from duck hepatitis virus and human hepatitis virus and its production
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2189254C2 (en) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Vaccines against hepatitis viruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07252300A (en) * 1994-03-11 1995-10-03 Immuno Japan:Kk Antigen fused protein from duck hepatitis virus and human hepatitis virus and its production
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHANG C ET AL: "Phenotypic mixing between different hepadnavirus nucleocapsid proteins reveals C protein dimerization to be cis preferential", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 68, no. 8, August 1994 (1994-08-01), pages 5225 - 5231, XP002130379, ISSN: 0022-538X *
HORWICH A L ET AL: "SYNTHESIS OF HEPADNAVIRUS PARTICLES THAT CONTAIN REPLICATION-DEFECTIVE DUCK HEPATITIS B VIRUS GENOMES IN CULTURED HUH7 CELLS", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 64, no. 2, 1 February 1990 (1990-02-01), pages 642 - 650, XP000283078, ISSN: 0022-538X *
KENNEY JOHN M ET AL: "Evolutionary conservation in the hepatitis B virus core structure: Comparison of human and duck cores", STRUCTURE (LONDON), vol. 3, no. 10, 1995, pages 1009 - 1019, XP004587927, ISSN: 0969-2126 *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 02 29 February 1996 (1996-02-29) *
SCHOEDEL F ET AL: "HEPATITIS B VIRUS CORE AND E ANTIGEN: IMMUNE RECOGNITION AND USE ASA VACCINE CARRIER MOIETY", INTERVIROLOGY, XX, XX, vol. 39, no. 1/2, 1996, pages 104 - 110, XP000891467, ISSN: 0300-5526 *
See also references of WO0046365A1 *

Also Published As

Publication number Publication date
AU2977500A (en) 2000-08-25
WO2000046365A1 (en) 2000-08-10
EP1165773A1 (en) 2002-01-02
JP2003520568A (en) 2003-07-08

Similar Documents

Publication Publication Date Title
HUP0202885A3 (en) Vaccines
GB9911569D0 (en) Antibodies
EP1165773A4 (en) Advanced antigen presentation platform
EP1213621A4 (en) Developing device
GB9901254D0 (en) Vaccines
GB9905817D0 (en) Methods
GB9930591D0 (en) Component for vaccine
GB9929937D0 (en) Antigen delivery
GB9915419D0 (en) Antigens
GB9904312D0 (en) Platform
GB9825184D0 (en) Antigen
AU7788600A (en) Colon-tumour-associated antigens
GB9908719D0 (en) Movable platform
GB2354793B (en) Access platform
GB9930585D0 (en) Component for vaccine
GB9929923D0 (en) Antigen preparations
PL109287U1 (en) Platform
GB2355858B (en) Ioniser platform
GB9908525D0 (en) Methods
AUPQ477299A0 (en) Relocatable platform
GB9928197D0 (en) 85kDA antigen
GB9918051D0 (en) Antibodies
GB0212763D0 (en) Antibodies
GB9927698D0 (en) Therapeutic antibody
GB9929298D0 (en) Free-standing access platform

Legal Events

Date Code Title Description
PUAJ Public notification under rule 129 epc

Free format text: ORIGINAL CODE: 0009425

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOCACHE PHARMACEUTICALS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20041123

17Q First examination report despatched

Effective date: 20050609

17Q First examination report despatched

Effective date: 20050609

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101AFI20071008BHEP

Ipc: C07K 14/02 20060101ALN20071008BHEP

Ipc: A61K 39/385 20060101ALN20071008BHEP

Ipc: C07K 14/00 20060101ALI20071008BHEP

Ipc: C12N 7/04 20060101ALN20071008BHEP

Ipc: A61K 39/39 20060101ALN20071008BHEP

RTI1 Title (correction)

Free format text: ADVANCED ANTIGEN PRESENTATION PLATFORM AND ADJUVANT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080313